Telum new

TELUM THERAPEUTICS

The science of today is the technology of tomorrow

Biotech | Antimicrobials | Multidrug resistance | Phage Therapy

Description

In Telum we believe nature is wise and we learn from the best properties of natural LYSins (LYS) to select them and construct from there, engineered phage lytic enzymes (EPLEs) with enhanced antimicrobial activities. NPLEs are phage produced by the phage during the infection cycle or form part of the virion structure, and are responsible for degradation of the peptidoglycan layer of the host bacterium in two important steps, lysis from without inyecting the genome of the phage and the lysis from withtin at the end of the lytic cycle to release new viral progeny.
 
EPLEs are engineered proteins result as combination of different activity modules, that confers the final synthetic product enhanced antimicrobial activity or resistance to hazardous environmental conditions, or an advantage when treating an infection.
 
FRANK are modifications of the most active candidates to create a consensus sequences using what is usually found in nature.
 
By connecting chemistry and physics of proteins with machine learning, Telum is leveraging the combinative potential of LYS and protein engineering to advance in new research.

Featured proyects

  • Awarded as one of the top 100 ideas of the year in 2022 in Spain (by Actualidad Económica in collaboration with Caixa Bank and ABG Intellectual Property). (read more)
 
  • Selected as one of the 9 companies in the world by Mayo Clinic and the University of Arizona to participate in their business development pro. (read more)
 
  • Attained CE marking and FDA 510(k) clearance for the WasherCap device.
 
  • Presented at the Musculoskeletal New Ventures Conference 2022 (the only Spanish company to be invited and not from the United States). (read more)
 
Abanza